Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel cancer therapeutics. Headquartered in Doylestown, Pennsylvania, the company's mission is to create groundbreaking, precision therapies for genetically defined cancers by targeting DNA damage response (DDR) pathways. This approach aims to improve patient survival and quality of life while minimizing treatment-related toxicity.

Aprea's pipeline focuses on small molecule inhibitors designed to exploit genetic mutations in cancer cells. Its lead programs include APR-1051, an oral WEE1 inhibitor, and ATRN-119 (Mosipasertib), a macrocyclic ATR inhibitor, both of which are in clinical development for various solid tumor indications. These therapies are being explored for applications across multiple cancer types, including ovarian, colorectal, prostate, breast, endometrial, and HPV-positive head and neck cancers.

Recent notable developments for Aprea Therapeutics include the closing of an oversubscribed $30 million private placement in April 2026. In March 2026, the company reported positive emerging clinical activity for its WEE1 inhibitor, APR-1051, including confirmed partial responses in the ongoing Phase 1 ACESOT-1051 trial. Leadership is provided by Oren Gilad, Ph.D., who has served as President and Chief Executive Officer since July 2022. The company continues to strengthen its global patent portfolio in DDR cancer therapeutics.